Bilimsel çalışmalar

Prof. Dr. Mehmet Hilmi Doğu

125 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. VEXAS Syndrome and IgG4-Related Disease: Coincidental Association or Pathogenetic Link?

    Mediterranean journal of rheumatology, 2026

    DOI 10.31138/mjr.230126.epr PMID 42100070 Açık erişimli tam metinKaynak: ORCID

  2. Follicular Lymphoma: Frequency and Timing of Treatment: Single Center Experience

    Istanbul Medical Journal, 2025

    DOI 10.4274/imj.galenos.2025.20788 Açık erişimli tam metinKaynak: OpenAlex

  3. Evaluation of The Relationship Between Bone Marrow Changes and Hemogram Findings in HIV-Positive Patients

    Namık Kemal Tıp Dergisi, 2025

    DOI 10.4274/nkmj.galenos.2025.29494 Açık erişimli tam metinKaynak: OpenAlex

  4. Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety

    Indian Journal of Hematology and Blood Transfusion, 2025

    DOI 10.1007/s12288-025-02093-w PMID 42040698 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  5. Acinetobacter baumannii in Hematology Practice: Clinical Factors Affecting the Course of Infection

    Acta haematologica oncologica Turcica., 2024

    DOI 10.4274/ahot.galenos.2024.2024-9-3 Açık erişimli tam metinKaynak: OpenAlex

  6. Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

    Hitit Medical Journal, 2024

    DOI 10.52827/hititmedj.1320606 Açık erişimli tam metinKaynak: OpenAlex

  7. A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

    Istanbul Medical Journal, 2023

    DOI 10.4274/imj.galenos.2023.66742 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  8. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

    Journal of Chemotherapy, 2023

    DOI 10.1080/1120009x.2023.2208439 PMID 37211906 3 atıf (Europe PMC) Kaynak: ORCID

  9. AAT: does it have a place in acute leukemia?

    Biomarkers in Medicine, 2023

    DOI 10.2217/bmm-2023-0415 PMID 38197403 Kaynak: ORCID

  10. Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results

    Mediterranean Journal of Hematology and Infectious Diseases, 2023

    DOI 10.4084/mjhid.2023.031 PMID 37180209 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  11. PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000974412.42102.11 Açık erişimli tam metinKaynak: OpenAlex

  12. The Association Between Red Cell Distribution Width and Bone Marrow Fibrosis in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

    Kocaeli Medical Journal, 2022

    DOI 10.5505/ktd.2022.69926 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  13. Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG),Non-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışması

    Turkish Journal of Hematology, 2022

    DOI 10.4274/tjh.galenos.2022.2022.0052 PMID 35678126 Açık erişimli tam metinKaynak: ORCID

  14. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

    Clinical Lymphoma, Myeloma and Leukemia, 2022

    DOI 10.1016/j.clml.2021.09.010 PMID 34629286 5 atıf (Europe PMC) Kaynak: ORCID

  15. Efficacy of the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) to reduce the need for X-ray in pregnant patients with COVID-19

    Journal of Perinatal Medicine, 2022

    DOI 10.1515/jpm-2021-0341 PMID 35488442 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  16. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

    Internal and Emergency Medicine, 2022

    DOI 10.1007/s11739-021-02784-y PMID 34110562 17 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  17. Quality of Life Assessment with EORTC QLQ in Patients with Hodgkin Lymphoma: Multicenter Study

    Acta Oncologica Turcica, 2022

    DOI 10.5505/aot.2022.25991 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  18. Quality of Life Assessment with EORTC QLQ in Patients with Multiple Myeloma: Multicenter Study

    Forbes Journal of Medicine, 2022

    DOI 10.4274/forbes.galenos.2022.04274 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  19. Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

    Hematological Oncology, 2021

    DOI 10.1002/hon.2897 PMID 34171130 15 atıf (Europe PMC) Kaynak: OpenAlex

  20. HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)01845-0 Kaynak: OpenAlex

  21. Poster: HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/s2152-2650(21)01484-1 Kaynak: OpenAlex

  22. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/j.clml.2021.04.004 PMID 34059487 9 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  23. Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey.

    PubMed, 2021

    PMID 34565016 Açık erişimli tam metinKaynak: OpenAlex

  24. Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey

    AYBU AVESIS, 2021

    Kaynak: OpenAlex

  25. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data,Kronik Lenfositik Lösemili Hastalarda İbrutinib Tedavisinin Etkililiği ve Güvenilirliği: Gerçek Hayat Verilerinin Retrospektif Analizi

    Turkish Journal of Hematology, 2021

    DOI 10.4274/tjh.galenos.2021.2021.0007 PMID 34448556 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  26. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience

    Annals of Hematology, 2021

    DOI 10.1007/s00277-021-04554-4 PMID 33988739 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  27. Relaps/Refrakter Lenfoma (Mantle Hücreli Lenfoma Hariç) Hastalarında Lenalidomid Bazlı Tedavi Sonuçları: Çok Merkezli Sonuçlar

    LLM Dergi, 2021

    DOI 10.5578/llm.20219602 Açık erişimli tam metinKaynak: ORCID

  28. The Use of Hypomethylating Agents in Hematologic Malignancies: Treatment Preferences and Results

    International Journal of Hematologic Oncology, 2021

    DOI 10.2217/ijh-2020-0019 PMID 35295753 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  29. Mucormycosis in Hematologic Malignancies: Clinical Follow-Up and Treatment Results

    Istanbul Medical Journal, 2021

    DOI 10.4274/imj.galenos.2021.65872 Açık erişimli tam metinKaynak: ORCID

  30. Subgroup Analysis in Multiple Myeloma Patients under Sixty Years: A Single-Center Study

    Istanbul Medical Journal, 2021

    DOI 10.4274/imj.galenos.2021.62593 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  31. COVID-19 clinical course and blood groups: Turkish population-based study

    Turkish Journal of Medical Sciences, 2021

    DOI 10.3906/sag-2101-321 PMID 33957720 12 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  32. COVID-19 in hematopoietic cell transplant recipients

    Bone Marrow Transplantation, 2021

    DOI 10.1038/s41409-020-01084-x PMID 33110186 27 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  33. Convalescent plasma therapy in patients with COVID-19

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021

    DOI 10.1016/j.transci.2020.102955 PMID 33011076 39 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  34. Hemolytic anemia and plasma exchange

    Transfusion and Apheresis Science, 2021

    DOI 10.1016/j.transci.2021.103245 PMID 34412947 4 atıf (Europe PMC) Kaynak: ORCID

  35. Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single-centre study

    Mycoses, 2021

    DOI 10.1111/myc.13265 PMID 33683715 15 atıf (Europe PMC) Kaynak: ORCID

  36. The outcome of COVID-19 in patients with hematological malignancy

    Journal of Medical Virology, 2021

    DOI 10.1002/jmv.26404 PMID 32776581 91 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  37. An Experience on Pomalidomide in Patients within Relapsed/Refractory Multiple Myeloma - A Multicenter Study in Turkey

    Journal of Pharmaceutical Research International, 2021

    DOI 10.9734/jpri/2020/v32i4131047 Açık erişimli tam metinKaynak: ORCID

  38. A new FLT3 inhibitor with two cases: the gilteritinib experience

    American Journal of Blood Research, 2021

    PMID 34322291 Açık erişimli tam metinKaynak: ORCID

  39. NK/T-Hücreli Büyük Granüler Lenfositik Lösemi

    2021

    Kaynak: OpenAlex

  40. BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’xxS LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE

    AYBU AVESIS, 2020

    Kaynak: OpenAlex

  41. Beta Thalassemia Minor: Patients Are Not Tired but Depressed and Anxious

    Medical Principles and Practice, 2020

    DOI 10.1159/000508981 PMID 32460294 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  42. Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort Study

    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2020

    DOI 10.4274/tjh.galenos.2019.2019.0177 PMID 31630512 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  43. A Rare Disease in the Differential Diagnosis of Chylothorax: Waldenström’s Macroglobulinaemia

    Istanbul Medical Journal, 2020

    DOI 10.4274/imj.galenos.2020.56750 Açık erişimli tam metinKaynak: ORCID

  44. Fever of Unknown Origin: A Patient with Intermittent Idiopathic Fever for Three Years

    Istanbul Medical Journal, 2020

    DOI 10.4274/imj.galenos.2020.71084 Açık erişimli tam metinKaynak: ORCID

  45. Evaluation of the Relationship Between Initial Lymphocyte Count and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukaemia Patients

    Istanbul Medical Journal, 2020

    DOI 10.4274/imj.galenos.2020.46690 Açık erişimli tam metinKaynak: ORCID

  46. A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality

    Journal of Infection and Public Health, 2020

    DOI 10.1016/j.jiph.2020.09.009 PMID 33071210 16 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  47. An unexpected situation in isolated nasopharyngeal mass differential diagnosis: Solitary extramedullary plasmacytoma

    Otolaryngology Case Reports, 2020

    DOI 10.1016/j.xocr.2020.100246 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  48. COVID-19 Pneumonia or Hypereosinophilic Syndrome?

    Journal of Medical Cases, 2020

    DOI 10.14740/jmc3587 PMID 33984086 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  49. Evaluation of hepatitis b virus serology, antiviral use and reactivation hepatitis in hematologic malignancy patients,Hematolojik maligniteli hastalarda hepatit b virüs serolojileri, antiviral profilaksi ve reaktivasyon hepatit oranlarının değerlendirilmesi

    Turkiye Klinikleri Journal of Medical Sciences, 2020

    DOI 10.5336/medsci.2019-71432 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  50. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155220953198 PMID 32854573 27 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID